How do novel agents affect allogeneic transplantation in CLL?
New subtypes of acute lymphoblastic leukemia (ALL) – potential treatment identification by genomics
Preliminary results of ibruntinib in combination with FCR chemotherapy for CLL
Navigating advances in the myeloma landscape over the past couple of years
ROR1 and its role in CLL and other cancers